Physician profile
Guy T Petito
NPI 1629004999
$4,942.79
in general payments reported to CMS, 2019-2025
20 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $81.64 · 2021: $325 · 2022: $614 · 2023: $1,107 · 2024: $1,300 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,990 · Consulting Fee: $375 · Entertainment: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,990.25 |
| Consulting Fee | $375.00 |
| Entertainment | $130.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $710.79 | 2024-2025 | Hydrus Microstent, Rocklatan, Rhopressa |
| Bausch & Lomb Americas INC. | $602.51 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $483.38 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $406.26 | 2020-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $402.66 | 2023-2025 | Acuvue |
| Janssen Scientific Affairs, LLC | $375.00 | 2023 | |
| Abbvie INC. | $259.55 | 2022-2024 | |
| Optovue, INC. | $252.04 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $228.80 | 2019-2022 | |
| Horizon Therapeutics Plc | $228.72 | 2022-2023 | Tepezza |
| Optos, INC. | $130.17 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $130.14 | 2023-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $121.95 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $120.00 | 2025 | Xdemvy |
| Allergan, INC. | $117.87 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $113.09 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $107.21 | 2024 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $70.11 | 2023 | Lipiflow System Activator (Disposable) |
| Carl Zeiss Meditec, INC. | $63.14 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Petito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.